ASMB
Assembly Biosciences, Inc.
Price Chart
Latest Quote
$24.44
+0.29 (+1.20%)
Current Price
| Previous Close | $24.15 |
| Open | $24.59 |
| Day High | $25.93 |
| Day Low | $24.22 |
| Volume | 277,849 |
Stock Information
| Shares Outstanding | 19.82M |
| Total Debt | $2.49M |
| Cash Equivalents | $226.60M |
| Revenue | $71.10M |
| Net Income | $-6.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $484.33M |
| P/E Ratio | 305.50 |
| EPS (TTM) | $0.08 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $146.66M |
| Sales | $71.10M |
| Income | $-6.38M |
| Book/sh | $12.50 |
| Cash/sh | $11.43 |
| Employees | 73 |
Financial Ratios
| Quick Ratio | 6.52 |
| Current Ratio | 6.65 |
| Debt/Eq | 1.25 |
Returns & Margins
| ROA | -5.06% |
| ROE | -5.66% |
| Gross Margin | 8.77% |
| Operating Margin | -138.44% |
| Profit Margin | -8.98% |
Ownership
| Insider Ownership | 28.42% |
| Institutional Ownership | 48.36% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -11.61 |
| P/S | 6.81 |
| P/B | 1.96 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $50.00 |
Technical Indicators
| SMA20 | $24.88 |
| SMA50 | $27.18 |
| SMA200 | $28.88 |
| RSI | 30.07 |
| ATR | 1.4843 |
| Shares Float | 8.80M |
| Short Float | 11.41% |
| Short Ratio | 9.29 |
| Volatility | 1.08 |
| Rel Volume | 1.37 |
Performance History
| Week | +8.48% |
| Month | -7.84% |
| Quarter | -11.16% |
| 6 Months | -27.04% |
| YTD | -27.59% |
| Year | +43.09% |
| 3 Years | +88.58% |
| 5 Years | -53.50% |
| 10 Years | -65.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $24.44 | 298,900 |
| 2026-06-17 | $24.15 | 133,800 |
| 2026-06-16 | $23.33 | 116,900 |
| 2026-06-15 | $23.34 | 173,200 |
| 2026-06-12 | $22.96 | 144,400 |
| 2026-06-11 | $22.53 | 290,500 |
| 2026-06-10 | $22.26 | 195,500 |
| 2026-06-09 | $22.72 | 243,800 |
| 2026-06-08 | $22.56 | 153,100 |
| 2026-06-05 | $22.90 | 130,600 |
| 2026-06-04 | $24.11 | 215,200 |
| 2026-06-03 | $24.57 | 181,000 |
| 2026-06-02 | $24.49 | 276,600 |
| 2026-06-01 | $26.92 | 219,000 |
| 2026-05-29 | $27.66 | 138,800 |
| 2026-05-28 | $27.73 | 115,600 |
| 2026-05-27 | $27.40 | 149,000 |
| 2026-05-26 | $28.75 | 244,700 |
| 2026-05-22 | $28.34 | 893,900 |
| 2026-05-21 | $26.50 | 63,900 |
| 2026-05-20 | $26.26 | 121,800 |
| 2026-05-19 | $26.52 | 116,200 |
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
đ° Latest News
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
MarketBeat âĸ 2026-06-08T17:03:15Z
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
MarketBeat âĸ 2026-06-05T19:03:28Z
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
MarketBeat âĸ 2026-05-14T11:05:48Z
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts
Simply Wall St. âĸ 2026-05-13T11:29:08Z
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely
Simply Wall St. âĸ 2026-05-11T11:12:42Z
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T21:15:02Z
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Zacks âĸ 2026-03-19T21:20:01Z
Assembly Biosciences: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-19T20:26:32ZMetagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-03-05T22:30:03Z
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-02-26T22:30:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $72,303,000 | $28,520,000 | $7,163,000 | $0 |
| Operating Revenue | $72,303,000 | $28,520,000 | $7,163,000 | $0 |
| Expenses | ||||
| Total Expenses | $84,421,000 | $73,940,000 | $71,809,000 | $94,114,000 |
| Net Non Operating Interest Income Expense | $5,996,000 | $5,573,000 | $3,451,000 | $1,022,000 |
| Operating Expense | $84,421,000 | $73,940,000 | $71,809,000 | $94,114,000 |
| General And Administrative Expense | $19,608,000 | $18,007,000 | $22,909,000 | $24,134,000 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Net Interest Income | $5,996,000 | $5,573,000 | $3,451,000 | $1,022,000 |
| Interest Income | $5,996,000 | $5,573,000 | $3,451,000 | $1,022,000 |
| Normalized Income | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Net Income From Continuing And Discontinued Operation | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Total Operating Income As Reported | $-12,118,000 | $-45,420,000 | $-64,646,000 | $-94,114,000 |
| Net Income Common Stockholders | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Net Income | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Net Income Including Noncontrolling Interests | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Net Income Continuous Operations | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Pretax Income | $-6,122,000 | $-39,847,000 | $-61,195,000 | $-93,092,000 |
| Interest Income Non Operating | $5,996,000 | $5,573,000 | $3,451,000 | $1,022,000 |
| Operating Income | $-12,118,000 | $-45,420,000 | $-64,646,000 | $-94,114,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.55 | $-6.69 | $-13.38 | $-23.04 |
| Basic EPS | $-0.55 | $-6.69 | $-13.38 | $-23.04 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,989,000 | $-45,291,000 | $-64,196,000 | $-93,616,000 |
| Reconciled Depreciation | $129,000 | $129,000 | $450,000 | $498,000 |
| EBITDA (Bullshit earnings) | $-11,989,000 | $-45,291,000 | $-64,196,000 | $-93,616,000 |
| EBIT | $-12,118,000 | $-45,420,000 | $-64,646,000 | $-94,114,000 |
| Diluted Average Shares | $11,210,934 | $6,004,560 | $4,577,371 | $4,034,105 |
| Basic Average Shares | $11,210,934 | $6,004,560 | $4,577,371 | $4,034,105 |
| Diluted NI Availto Com Stockholders | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Tax Provision | $0 | $330,000 | $33,000 | $0 |
| Research And Development | $64,813,000 | $55,933,000 | $48,900,000 | $69,980,000 |
| Selling General And Administration | $19,608,000 | $18,007,000 | $22,909,000 | $24,134,000 |
| Other Gand A | $19,608,000 | $18,007,000 | $22,909,000 | $24,134,000 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Impairment Of Capital Assets | - | - | - | $0 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $206,751,000 | $33,359,000 | $41,097,000 | $82,664,000 |
| Total Assets | $257,590,000 | $119,168,000 | $136,823,000 | $101,794,000 |
| Total Non Current Assets | $3,041,000 | $3,665,000 | $3,036,000 | $4,827,000 |
| Other Non Current Assets | $312,000 | $312,000 | $312,000 | $889,000 |
| Current Assets | $254,549,000 | $115,503,000 | $133,787,000 | $96,967,000 |
| Other Current Assets | $5,469,000 | $3,424,000 | $3,497,000 | $4,413,000 |
| Receivables | $974,000 | $0 | $43,000 | $944,000 |
| Accounts Receivable | $974,000 | $0 | $43,000 | $944,000 |
| Cash Cash Equivalents And Short Term Investments | $248,106,000 | $112,079,000 | $130,247,000 | $91,610,000 |
| Cash And Cash Equivalents | $58,450,000 | $38,344,000 | $19,841,000 | $52,418,000 |
| Investmentin Financial Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $2,628,000 | $3,089,000 | $2,342,000 | $3,465,000 |
| Long Term Debt And Capital Lease Obligation | $2,059,000 | $2,628,000 | $1,122,000 | $101,000 |
| Current Debt And Capital Lease Obligation | $569,000 | $461,000 | $1,220,000 | $3,364,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $50,839,000 | $85,809,000 | $95,726,000 | $19,130,000 |
| Total Non Current Liabilities Net Minority Interest | $2,059,000 | $38,006,000 | $56,501,000 | $2,834,000 |
| Non Current Deferred Liabilities | $0 | $35,378,000 | $55,379,000 | $2,733,000 |
| Current Liabilities | $48,780,000 | $47,803,000 | $39,225,000 | $16,296,000 |
| Current Deferred Liabilities | $36,904,000 | $37,622,000 | $30,915,000 | $0 |
| Payables And Accrued Expenses | $3,784,000 | $3,242,000 | $1,606,000 | $6,704,000 |
| Payables | $1,171,000 | $585,000 | $461,000 | $2,493,000 |
| Accounts Payable | $1,171,000 | $585,000 | $461,000 | $2,493,000 |
| Equity | ||||
| Common Stock Equity | $206,751,000 | $33,359,000 | $41,097,000 | $82,664,000 |
| Total Equity Gross Minority Interest | $206,751,000 | $33,359,000 | $41,097,000 | $82,664,000 |
| Stockholders Equity | $206,751,000 | $33,359,000 | $41,097,000 | $82,664,000 |
| Gains Losses Not Affecting Retained Earnings | $-41,000 | $-211,000 | $-81,000 | $-803,000 |
| Other Equity Adjustments | $-41,000 | $-211,000 | $-81,000 | $-803,000 |
| Retained Earnings | $-832,047,000 | $-825,925,000 | $-785,748,000 | $-724,520,000 |
| Other | ||||
| Ordinary Shares Number | $15,855,329 | $7,457,240 | $5,482,751 | $4,074,581 |
| Share Issued | $15,855,329 | $7,457,240 | $5,482,751 | $4,074,581 |
| Tangible Book Value | $206,751,000 | $33,359,000 | $41,097,000 | $82,664,000 |
| Invested Capital | $206,751,000 | $33,359,000 | $41,097,000 | $82,664,000 |
| Working Capital | $205,769,000 | $67,700,000 | $94,562,000 | $80,671,000 |
| Capital Lease Obligations | $2,628,000 | $3,089,000 | $2,342,000 | $3,465,000 |
| Total Capitalization | $206,751,000 | $33,359,000 | $41,097,000 | $82,664,000 |
| Additional Paid In Capital | $1,038,823,000 | $859,488,000 | $826,921,000 | $807,983,000 |
| Capital Stock | $16,000 | $7,000 | $5,000 | $4,000 |
| Common Stock | $16,000 | $7,000 | $5,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $35,378,000 | $55,379,000 | $2,733,000 |
| Long Term Capital Lease Obligation | $2,059,000 | $2,628,000 | $1,122,000 | $101,000 |
| Current Deferred Revenue | $36,904,000 | $37,622,000 | $30,915,000 | $0 |
| Current Capital Lease Obligation | $569,000 | $461,000 | $1,220,000 | $3,364,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,523,000 | $6,478,000 | $5,484,000 | $6,228,000 |
| Current Accrued Expenses | $2,613,000 | $2,657,000 | $1,145,000 | $4,211,000 |
| Net PPE | $2,729,000 | $3,353,000 | $2,724,000 | $3,938,000 |
| Gross PPE | $2,729,000 | $3,353,000 | $2,724,000 | $5,625,000 |
| Other Properties | $2,729,000 | $3,353,000 | $2,724,000 | $3,297,000 |
| Other Short Term Investments | $189,656,000 | $73,735,000 | $110,406,000 | $39,192,000 |
| Accumulated Depreciation | - | - | $-210,000 | $-1,687,000 |
| Leases | - | - | $62,000 | $1,629,000 |
| Machinery Furniture Equipment | - | - | $238,000 | $699,000 |
| Properties | - | - | $0 | $0 |
| Investments And Advances | - | - | - | $0 |
| Other Investments | - | - | - | $0 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-41,159,000 | $-51,145,000 | $22,488,000 | $-84,565,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-41,093,000 | $-51,117,000 | $22,743,000 | $-84,463,000 |
| Cash Flow From Continuing Operating Activities | $-41,093,000 | $-51,117,000 | $22,743,000 | $-84,463,000 |
| Operating Gains Losses | $-3,000 | - | $139,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-66,000 | $-28,000 | $-255,000 | $-102,000 |
| Investing Cash Flow | $-113,468,000 | $40,171,000 | $-69,138,000 | $90,640,000 |
| Cash Flow From Continuing Investing Activities | $-113,468,000 | $40,171,000 | $-69,138,000 | $90,640,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $168,307,000 | $29,294,000 | $13,689,000 | $325,000 |
| Financing Cash Flow | $174,667,000 | $29,449,000 | $13,818,000 | $614,000 |
| Cash Flow From Continuing Financing Activities | $174,667,000 | $29,449,000 | $13,818,000 | $614,000 |
| Net Common Stock Issuance | $168,307,000 | $29,294,000 | $13,689,000 | $325,000 |
| Common Stock Issuance | $168,307,000 | $29,294,000 | $13,689,000 | $325,000 |
| Other | ||||
| End Cash Position | $58,450,000 | $38,344,000 | $19,841,000 | $52,418,000 |
| Beginning Cash Position | $38,344,000 | $19,841,000 | $52,418,000 | $45,627,000 |
| Changes In Cash | $20,106,000 | $18,503,000 | $-32,577,000 | $6,791,000 |
| Proceeds From Stock Option Exercised | $6,360,000 | $155,000 | $129,000 | $289,000 |
| Net Investment Purchase And Sale | $-113,402,000 | $40,199,000 | $-68,907,000 | $89,242,000 |
| Sale Of Investment | $116,432,000 | $130,700,000 | $65,015,000 | $116,825,000 |
| Purchase Of Investment | $-229,834,000 | $-90,501,000 | $-133,922,000 | $-27,583,000 |
| Net PPE Purchase And Sale | $-66,000 | $-28,000 | $-231,000 | $-102,000 |
| Purchase Of PPE | $-66,000 | $-28,000 | $-255,000 | $-102,000 |
| Change In Working Capital | $-38,279,000 | $-11,948,000 | $76,341,000 | $-2,122,000 |
| Change In Other Working Capital | $-36,096,000 | $-13,294,000 | $83,561,000 | - |
| Change In Other Current Liabilities | $-751,000 | $-1,400,000 | $-3,774,000 | $-3,670,000 |
| Change In Payables And Accrued Expense | $1,587,000 | $2,630,000 | $-5,840,000 | $14,000 |
| Change In Accrued Expense | $1,001,000 | $2,506,000 | $-3,808,000 | $180,000 |
| Change In Payable | $586,000 | $124,000 | $-2,032,000 | $-166,000 |
| Change In Account Payable | $586,000 | $124,000 | $-2,032,000 | $-166,000 |
| Change In Prepaid Assets | $-2,045,000 | $73,000 | $916,000 | $1,328,000 |
| Change In Receivables | $-974,000 | $43,000 | $901,000 | $-608,000 |
| Changes In Account Receivables | $-974,000 | $43,000 | $901,000 | $-608,000 |
| Other Non Cash Items | $851,000 | $1,417,000 | $3,507,000 | $3,505,000 |
| Stock Based Compensation | $4,677,000 | $3,120,000 | $5,119,000 | $6,593,000 |
| Amortization Of Securities | $-2,346,000 | $-3,658,000 | $-1,585,000 | $155,000 |
| Depreciation Amortization Depletion | $129,000 | $129,000 | $450,000 | $498,000 |
| Depreciation And Amortization | $129,000 | $129,000 | $450,000 | $498,000 |
| Gain Loss On Investment Securities | $-3,000 | - | - | - |
| Net Income From Continuing Operations | $-6,122,000 | $-40,177,000 | $-61,228,000 | $-93,092,000 |
| Income Tax Paid Supplemental Data | - | $421,000 | $0 | - |
| Sale Of PPE | - | $0 | $24,000 | $0 |
| Change In Other Current Assets | - | $0 | $577,000 | $814,000 |
| Gain Loss On Sale Of PPE | - | $0 | $139,000 | $0 |
| Net Business Purchase And Sale | - | - | $0 | $1,500,000 |
| Sale Of Business | - | - | $0 | $1,500,000 |
| Asset Impairment Charge | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Purchase Of Intangibles | - | - | - | - |
Fetched: 2026-06-19